中国药房Issue(21)：2947-2949,3.DOI:10.6039/j.issn.1001-0408.2015.21.25
噻托溴铵治疗慢性阻塞性肺疾病有效性和安全性的Meta分析
Meta-analysis of Efficacy and Safety of Tiotropium Bromide in the Treatment of COPD
摘要
Abstract
OBJECTIVE:To evaluate the efficacy and safety of tiotropium bromide in the treatment of COPD patients and pro-vide evidence-based reference for the clinical treatment. METHODS:PubMed,EMBase,Medline,Cochrane Library,CJFD,Wan-Fang and VIP database were retrieved to collect the randomized controlled trial(RCT)of tiotropium bromide(test group)vs. place-bo(control group)in the treatment of COPD. The data was extracted and the quality was evaluated by Rev Man 5.0 software. RE-SULTS:A total of 19 studies were included,involving 16 318 patients. Meta-analysis shows that the FEV1[MD=0.13,95%CI (0.12,0.14),P<0.001],FVC[MD=0.20,95%CI(0.20,0.25),P<0.001] in test group were higher than control group,SGRQ score [MD=-2.94,95%CI(-3.38,-2.49),P<0.001] and COPD exacerbation rate[RR=0.83,95%CI(0.77,0.90),P<0.001] in test group were lower than those in control group ,but the dry mouth rate was higher than that of control group[RR=2.07,95%CI(1.34, 3.20),P<0.001],there were significant differences in 2 groups . CONCLUSIONS:Tiotropium bromide has good efficacy in the treatment of COPD. However,it may cause dry mouth. Due to the methodological limitations of included studies,it remians to be further verified by large-sample and high-quality RCT.关键词
噻托溴铵/慢性阻塞性肺疾病/Meta分析/疗效/安全性Key words
Tiotropium bromide/COPD/Meta-analysis/Efficacy/Safety分类
医药卫生引用本文复制引用
任艳平,石蕊,张睿,王倩,李岑,卢丹丹,赵可新..噻托溴铵治疗慢性阻塞性肺疾病有效性和安全性的Meta分析[J].中国药房,2015,(21):2947-2949,3.基金项目
国家科技支撑计划子课题 （）
